Zhenyi Hu

1.2k total citations
17 papers, 838 citations indexed

About

Zhenyi Hu is a scholar working on Molecular Biology, Immunology and Epidemiology. According to data from OpenAlex, Zhenyi Hu has authored 17 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Immunology and 3 papers in Epidemiology. Recurrent topics in Zhenyi Hu's work include Immune Response and Inflammation (5 papers), Protein Degradation and Inhibitors (4 papers) and Ubiquitin and proteasome pathways (4 papers). Zhenyi Hu is often cited by papers focused on Immune Response and Inflammation (5 papers), Protein Degradation and Inhibitors (4 papers) and Ubiquitin and proteasome pathways (4 papers). Zhenyi Hu collaborates with scholars based in China, United States and Norway. Zhenyi Hu's co-authors include Craig M. Crews, Hang Yin, Saul Jaime‐Figueroa, Jie Zhang, Xiaole Qi, Jiabi Zhu, Po‐Han Chen, Scott A. Holley, Kusal T. G. Samarasinghe and Dhanusha A. Nalawansha and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Zhenyi Hu

17 papers receiving 817 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenyi Hu China 12 466 229 184 83 69 17 838
Andrew R. Griswold United States 15 841 1.8× 375 1.6× 179 1.0× 116 1.4× 79 1.1× 17 1.1k
Banmeet S. Anand United States 20 344 0.7× 106 0.5× 386 2.1× 159 1.9× 163 2.4× 38 1.0k
Dirk Kuck Germany 14 691 1.5× 377 1.6× 80 0.4× 34 0.4× 93 1.3× 17 1.4k
Francesca Blasco Switzerland 14 426 0.9× 44 0.2× 145 0.8× 78 0.9× 49 0.7× 20 897
Bing Lu China 16 382 0.8× 74 0.3× 201 1.1× 36 0.4× 73 1.1× 34 771
Adolfo Cuesta United States 7 541 1.2× 465 2.0× 165 0.9× 12 0.1× 49 0.7× 7 1.1k
Stephen Brand United Kingdom 18 476 1.0× 105 0.5× 104 0.6× 27 0.3× 172 2.5× 26 999
Ben‐Fillippo Krippendorff Switzerland 11 439 0.9× 124 0.5× 189 1.0× 10 0.1× 27 0.4× 17 763
Anton Cheltsov United States 13 338 0.7× 70 0.3× 105 0.6× 8 0.1× 93 1.3× 19 640
Gilles A. Robichaud Canada 18 527 1.1× 174 0.8× 106 0.6× 6 0.1× 43 0.6× 53 927

Countries citing papers authored by Zhenyi Hu

Since Specialization
Citations

This map shows the geographic impact of Zhenyi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenyi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenyi Hu more than expected).

Fields of papers citing papers by Zhenyi Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenyi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenyi Hu. The network helps show where Zhenyi Hu may publish in the future.

Co-authorship network of co-authors of Zhenyi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenyi Hu. A scholar is included among the top collaborators of Zhenyi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenyi Hu. Zhenyi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Li, Wenxue, Abhijit Dasgupta, Ka Yang, et al.. (2025). Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions. Cell. 188(8). 2267–2287.e21. 5 indexed citations
2.
Hu, Zhenyi, Po‐Han Chen, Jacques Saarbach, et al.. (2024). EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling. Science Advances. 10(13). eadj7251–eadj7251. 18 indexed citations
3.
Li, Wenxue, Shisheng Wang, Barbora Šalovská, et al.. (2023). An optogenetic-phosphoproteomic study reveals dynamic Akt1 signaling profiles in endothelial cells. Nature Communications. 14(1). 3803–3803. 14 indexed citations
4.
Šalovská, Barbora, et al.. (2023). A basic phosphoproteomic-DIA workflow integrating precise quantification of phosphosites in systems biology. Biophysics Reports. 9(2). 82–98. 2 indexed citations
5.
Hu, Zhenyi, Po‐Han Chen, Wenxue Li, et al.. (2023). Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality. Journal of the American Chemical Society. 145(7). 4045–4055. 53 indexed citations
6.
Hu, Zhenyi, et al.. (2021). Protocol for evaluation and validation of TLR8 antagonists in HEK-Blue cells via secreted embryonic alkaline phosphatase assay. STAR Protocols. 3(1). 101061–101061. 5 indexed citations
7.
Samarasinghe, Kusal T. G., Saul Jaime‐Figueroa, Michael Burgess, et al.. (2021). Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras. Cell chemical biology. 28(5). 648–661.e5. 124 indexed citations
8.
Hu, Zhenyi & Craig M. Crews. (2021). Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic. ChemBioChem. 23(2). e202100270–e202100270. 150 indexed citations
9.
Chen, Po‐Han, et al.. (2021). Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). ACS Chemical Biology. 16(12). 2808–2815. 81 indexed citations
10.
Haug, Markus, Marianne Sandvold Beckwith, Claire Louet, et al.. (2020). Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nature Communications. 11(1). 147–147. 66 indexed citations
11.
Ehrnström, Birgitta, Liv Ryan, Siv Helen Moen, et al.. (2020). TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria. Journal of Leukocyte Biology. 107(4). 673–683. 11 indexed citations
12.
Moen, Siv Helen, Birgitta Ehrnström, Maria Yurchenko, et al.. (2019). Human Toll-like Receptor 8 (TLR8) Is an Important Sensor of Pyogenic Bacteria, and Is Attenuated by Cell Surface TLR Signaling. Frontiers in Immunology. 10. 1209–1209. 51 indexed citations
13.
Hu, Zhenyi, Hiromi Tanji, Shuting Zhang, et al.. (2018). Small-Molecule TLR8 Antagonists via Structure-Based Rational Design. Cell chemical biology. 25(10). 1286–1291.e3. 45 indexed citations
14.
Xia, Tingting, Zhenyi Hu, Wenzhi Ji, et al.. (2017). Synthesis of withasomnine and pyrazole derivatives via intramolecular dehydrogenative cyclization, as well as biological evaluation of withasomnine-based scaffolds. Organic Chemistry Frontiers. 5(5). 850–854. 12 indexed citations
15.
Zhang, Shuting, Zhenyi Hu, Hiromi Tanji, et al.. (2017). Small-molecule inhibition of TLR8 through stabilization of its resting state. Nature Chemical Biology. 14(1). 58–64. 99 indexed citations
16.
Chen, Hongyu, Zhenyi Hu, Chunping Tang, et al.. (2013). Dictamins A–C, three unprecedented apotirucallane-type trinortriterpenoids from Dictamnus dasycarpus. Tetrahedron Letters. 54(32). 4150–4153. 5 indexed citations
17.
Qi, Xiaole, et al.. (2011). Self-double-emulsifying drug delivery system (SDEDDS): A new way for oral delivery of drugs with high solubility and low permeability. International Journal of Pharmaceutics. 409(1-2). 245–251. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026